The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.

① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.

cls.cnDec 13, 2024 18:33

Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be partnered with imeik technology development? | Interpretations

1. imeik technology development's performance in the first three quarters has shown some growth, but the growth rates of revenue and net income attributable to the parent have slowed down. 2. In search of new performance growth points, imeik technology development's research and development expenses continue to rise, laying out in areas such as weight management drugs and botulinum toxin.

cls.cnOct 23, 2024 23:43

imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch

In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.

wallstreetcnOct 23, 2024 21:43

Revenue and net profit growth rates have both slowed down. Is Jinbo Life Sciences, which has been frequently accused, feeling the pressure? | interpretations

①In the first three quarters of this year, Jinbo Bioscience's performance still maintained a high-speed growth, but the growth rate slowed down compared to the same period last year. ②In addition, the rapid growth of the company's sales expenses was caused by reasons such as the expansion of the sales team. ③The company's core product, Weiyi Mei, is facing multiple pressures, so Jinbo Bioscience has frequently stated its posture in the face of internet-related sales platforms.

cls.cnOct 22, 2024 00:03

The performance is "double- declining" and the stock price is "constantly falling". Why did the growth engine of Bloomage Biotechnology Corporation Limited lose momentum?

bloomage biotechnology corporation limited once again experienced a phenomenon of declining revenue and net income in the first half of the year. The company achieved revenue of 2.81 billion yuan, a year-on-year decrease of 8.61%; achieved net income of 0.342 billion yuan, a year-on-year decrease of 19.51%; Although the raw materials business and medical terminal business performed well, the two new major sectors strongly promoted in recent years—functional skincare products and functional foods—have both experienced simultaneous declines in growth rate.

cls.cnAug 24, 2024 10:23